Memory Pharmaceuticals (MEMY) Achieves Enrollment Goal for Phase 2 Trial of MEM 3454
More News related to MEMY
- Roche (RHHBY) Purchases Shares of Memory Pharmaceuticals (MEMY) in Tender Offer
- Notable Mergers and Acquisitions of the Day 11/25: BHP/RTP, MEMY
- Roche Signs Agreement to Acquire Memory Pharmaceuticals (MEMY) For $50 Million
- Memory Pharmaceuticals (MEMY) Achieves Enrollment Goal for Phase 2 Trial of MEM 3454
- Memory Pharmaceuticals (MEMY) Announces 55% Reduction in Workforce; Appoints Smith as CFO
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it has achieved the enrollment goal for its Phase 2 trial of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cognitive impairment associated with schizophrenia. The Company has randomized 212 patients in the Phase 2 trial, triggering a $5.0 million payment from its partner Roche. Memory Pharmaceuticals expects to report top-line results from the trial by the end of April 2009.
The trial is designed to include approximately 212 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects in the study are randomized to receive 5 mg, 15 mg or 50 mg of R3487/MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effectiveness of R3487/MEM 3454 in CIAS using the MATRICS Consensus Cognitive Battery. Secondary objectives include assessing the effectiveness of the drug to improve other symptoms of schizophrenia and functional capacity.
Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
